MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
MacroGenics announced that Gilead Sciences has exercised an option to license a preclinical bispecific program, triggering a $10 million payment to MacroGenics under their existing collaboration agreement. The licensed program utilizes MacroGenics' TRIDENT platform to target solid tumors and is the second preclinical program to be advanced under the 2022 partnership alongside the clinical-stage MGD024.
Key figures
- Milestone payment
- 10000000
- Potential milestone value
- $1.6 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.